Literature DB >> 8444007

Intravenously injected radiolabelled fatty acids image brain tumour phospholipids in vivo: differential uptakes of palmitate, arachidonate and docosahexaenoate.

T Nariai1, N H Greig, J J DeGeorge, S Genka, S I Rapoport.   

Abstract

This paper investigates the incorporation of intravenously (i.v.) administered radiolabelled fatty acids--[9,10(3)-H]palmitate (3H-PA), [1-14C]arachidonate (14C-AA) and [1-14C]docosahexaenoate (14C-DHA)--into intracerebrally implanted tumours in awake Fischer-344 rats. A suspension of Walker 256 carcinosarcoma tumour cells (1 x 10(6) cells) was implanted into the right cerebral hemisphere of 8- to 9-week-old rats. Seven days after implantation, the awake rat was infused i.v. for 5 min with 3H-PA (6.4 mCi/kg), 14C-AA (170 microCi/kg) or 14C-DHA (100 microCi/kg). Twenty minutes after the start of infusion, the rat was killed and coronal brain sections were obtained for quantitative autoradiography and histology. Each fatty acid showed well-demarcated incorporation into tumour tissue. Areas of necrosis or haemorrhage showed no or small levels of incorporation. The ratios of incorporation into the tumour to incorporation into contralateral brain regions were 2.8-5.5 for 3H-PA, 2.1-3.3 for 14C-AA and 1.5-2.2 for 14C-DHA. The mean ratios differed significantly between the fatty acids (P < 0.01). 3H-PA was not incorporated into necrotic tumours despite the presence of an open blood-tumour barrier, indicated by extravasated horseradish peroxidase. The incorporation rate constant of 3H-PA was similar for small intracerebral and large extracerebral tumours. The results show that 3H-PA, 14C-AA and 14C-DHA are incorporated more readily into tumour tissue than into brain, and that the increase is primarily due to increased utilization of fatty acids by tumour cells and not due to a high blood-tumour permeability. The relative increases in rates of incorporation for the different fatty acids may be related to lipid composition of the tumour and to the requirement of and specific role of these fatty acids in tumour cell growth and division.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8444007     DOI: 10.1007/bf00114972

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  42 in total

1.  Studies on the turnover of plasma membranes in cultured mammalina cells. I. Rates of synthesis and degradation of plasma membrane proteins and carbohydrates.

Authors:  J Kaplan; M Moskowitz
Journal:  Biochim Biophys Acta       Date:  1975-05-06

2.  A study of phosphate, desoxyribonucleic acid, and phospholipid fractions in neural tumors.

Authors:  S N NAYYAR
Journal:  Neurology       Date:  1963-04       Impact factor: 9.910

Review 3.  Treatment of brain tumors.

Authors:  M D Walker
Journal:  Med Clin North Am       Date:  1977-09       Impact factor: 5.456

4.  Lipoxygenase metabolites of arachidonic acid as second messengers for presynaptic inhibition of Aplysia sensory cells.

Authors:  D Piomelli; A Volterra; N Dale; S A Siegelbaum; E R Kandel; J H Schwartz; F Belardetti
Journal:  Nature       Date:  1987 Jul 2-8       Impact factor: 49.962

5.  Phospholipids and glycolipids of tumours in the central nervous system.

Authors:  H O Lou; J Clausen; F Bierring
Journal:  J Neurochem       Date:  1965-07       Impact factor: 5.372

6.  Blood-brain barrier integrity and host responses in experimental metastatic brain tumours.

Authors:  N H Greig; H B Jones; J B Cavanagh
Journal:  Clin Exp Metastasis       Date:  1983 Jul-Sep       Impact factor: 5.150

7.  Metabolism of fatty acids by cultured tumor cells and their diploid precursor fibroblasts.

Authors:  L W Daniel; L S Kucera; M Waite
Journal:  J Biol Chem       Date:  1980-06-25       Impact factor: 5.157

8.  A new specific, sensitive and non-carcinogenic reagent for the demonstration of horseradish peroxidase.

Authors:  J S Hanker; P E Yates; C B Metz; A Rustioni
Journal:  Histochem J       Date:  1977-11

9.  Increasing annual incidence of primary malignant brain tumors in the elderly.

Authors:  N H Greig; L G Ries; R Yancik; S I Rapoport
Journal:  J Natl Cancer Inst       Date:  1990-10-17       Impact factor: 13.506

10.  A method for examining turnover and synthesis of palmitate-containing brain lipids in vivo.

Authors:  P J Robinson; S I Rapoport
Journal:  Clin Exp Pharmacol Physiol       Date:  1989-09       Impact factor: 2.557

View more
  5 in total

Review 1.  Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain.

Authors:  A A Spector
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

2.  Imaging decreased brain docosahexaenoic acid metabolism and signaling in iPLA(2)β (VIA)-deficient mice.

Authors:  Mireille Basselin; Angelo O Rosa; Epolia Ramadan; Yewon Cheon; Lisa Chang; Mei Chen; Deanna Greenstein; Mary Wohltmann; John Turk; Stanley I Rapoport
Journal:  J Lipid Res       Date:  2010-08-04       Impact factor: 5.922

3.  Differences in rates of incorporation of intravenously injected radiolabeled fatty acids into phospholipids of intracerebrally implanted tumor and brain in awake rats.

Authors:  T Nariai; J J DeGeorge; N H Greig; S Genka; S I Rapoport; A D Purdon
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

4.  Nuclear Factor of Activated T Cells-dependent Down-regulation of the Transcription Factor Glioma-associated Protein 1 (GLI1) Underlies the Growth Inhibitory Properties of Arachidonic Acid.

Authors:  Andrea Comba; Luciana L Almada; Ezequiel J Tolosa; Eriko Iguchi; David L Marks; Marianela Vara Messler; Renata Silva; Maite G Fernandez-Barrena; Elisa Enriquez-Hesles; Anne L Vrabel; Bruno Botta; Lucia Di Marcotulio; Volker Ellenrieder; Aldo R Eynard; Maria E Pasqualini; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

Review 5.  The eicosanoid cascade: possible role in gliomas and meningiomas.

Authors:  N Nathoo; G H Barnett; M Golubic
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.